| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Actuate Therapeutics (NASDAQ:ACTU) through any online brokerage.
Other companies in Actuate Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Actuate Therapeutics has a consensus price target of $13.67.
The stock price for Actuate Therapeutics (NASDAQ: ACTU) is $0.626 last updated October 9, 2026 at 7:21 PM EDT.
There are no upcoming dividends for Actuate Therapeutics.
Actuate Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Actuate Therapeutics.
Actuate Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
